Altimmune, Inc. Net Income Loss

• Altimmune, Inc. showed an increase of +7.3% in Net Income Loss from 2024 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Net Income Loss has declined by 152.8%.
• Historical annual values: Fiscal year 2025: -$88.09 million | Fiscal year 2024: -$95.06 million | Fiscal year 2023: -$88.45 million | Fiscal year 2022: -$84.71 million | Fiscal year 2021: -$97.09 million | Fiscal year 2020: -$49.04 million | Fiscal year 2019: -$20.52 million | Fiscal year 2018: -$39.17 million | Fiscal year 2017: -$46.43 million | Fiscal year 2016: -$11.09 million | Fiscal year 2015: -$3.44 million | Fiscal year 2014: -$9.96 million | Fiscal year 2013: -$11.72 million | Fiscal year 2012: -$4.92 million | Fiscal year 2011: -$3.80 million | Fiscal year 2010: -$34.85 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026